Westbrook Recovery

Suboxone Withdrawal Timeline in 2026: What the Studies Measured

Last updated

Suboxone withdrawal starts late and lasts long, and both facts come from one number: buprenorphine’s elimination half-life is 24 to 42 hours, so the drug is still there the morning after the last dose. Symptoms build over days rather than overnight, peak is a range rather than a date, and the long tail is sleep and mood rather than pain. The label’s own advice is to taper, and the measured surprise from the trials is this: shorter tapers feel harder the week after the last dose, but a longer taper has not been shown to work better on outcomes. The practical timeline below separates what was measured from what is folklore.

The short version

  1. It starts late because the drug leaves slowly — half-life 24 to 42 hours on the FDA label: withdrawal builds over days, not overnight
  2. The long tail is sleep and mood — the physical storm settles in the first weeks; broken sleep and flat mood are what linger
  3. Faster tapers feel harder, measurably — a sharp rise in the week after the last dose in the short-taper groups of the trials
  4. Longer was not proven better — the largest taper trial found no outcome advantage to 28 days over 7; population and aftercare decide more
  5. The dangerous part comes after — withdrawal itself is miserable, not fatal, in a healthy adult; the relapse after, with tolerance gone, is what kills

Step by step

  1. Get a prescriber, not a schedule from the internet

    A taper written for your dose, your history and your week beats any published timeline. The trials agree on this much: the plan has to fit the person.

  2. Plan the week after the last dose

    That week is the measured hot spot for short tapers. Sleep plan, time off, someone who knows. The people who plan it describe it as bad weather; the ones who do not describe it as a wall.

  3. Decide what comes after before the last dose

    Naltrexone or not, follow-up visits, the first month’s calendar. The trials with the best endings had a next step built in; the ones without it were just stopping.

  4. Carry the overdose warning out the door

    Tolerance falls fast during abstinence. If a lapse happens, the old dose is now an overdose. Anyone tapering off an opioid should have naloxone and someone who knows.

Two cards on why Suboxone withdrawal starts late: buprenorphine half-life 24 to 42 hours versus a few hours for most opioids
The drug is still there on day two. The bill arrives slow and pays out slowly.
Two cards on the shape of Suboxone withdrawal: not the next morning, days one and two stay quiet; it builds over days and eases over weeks
The peak is a band, not a date. Anyone selling an exact worst day is selling folklore.
Four cards for the order of Suboxone withdrawal symptoms: anxiety and restlessness first, then muscle aches sweats and chills, then stomach cramps and diarrhea, then broken sleep as the long tail
The physical storm settles in weeks. Sleep and mood are the tail, and the tail is what a plan is for.
What the FDA label says in plain words: typically milder than full agonists and delayed in onset, and taper rather than stop
Milder is real; delayed is the part that ambushes weekend plans. Taper is the label’s own advice.
Bar chart of Ling 2009: 44 percent abstinent at end of a 7-day taper versus 30 percent at 28 days, with no difference at 1 and 3 months
The largest taper trial found no advantage to going longer. Longer felt kinder elsewhere; it did not win here.

What the taper trials measured

Our analysis

Every timeline page publishes a day-by-day chart with no source. We read the randomized trials instead: seven of them, and they measured taper speed, not dates. What they found is more useful than the folklore.

44% vs 30%
abstinent at end of taper: 7-day vs 28-day (Ling 2009)
the shorter taper was not worse, even at the end
17% vs 13%
at 1 and 3 months after (same trial)
the early difference did not survive the follow-ups
sharp rise
the week after the last dose in 1-2 week tapers (Sigmon 2013)
the 4-week taper ran mild and stable by comparison
7 trials
in the Cochrane taper-speed review
too different to merge: the honest answer is a table, not a number
24-42 h
buprenorphine half-life on the FDA label
the reason it starts late and lasts long
0
seizure risk from opioid withdrawal itself
unlike alcohol or benzodiazepines; the fatal risk is the relapse after

How we got this: Read in full on 15 October 2026: Cochrane CD002025 taper-rate section, Sigmon 2013 (JAMA Psychiatry), Ling 2009 (CTN) figures, and the FDA label via DailyMed. The trial table and the conclusions are ours.

What these numbers cannot tell you: The trials are small, old and built for different populations; Cochrane could not meta-analyze them. They measured taper speed, not personal timelines. Your schedule belongs to your prescriber and your history.

Why it starts late and lasts long

Most opioid withdrawal timelines are really half-life tables in disguise, and Suboxone’s number is unusually long. The FDA label gives buprenorphine a mean elimination half-life of 24 to 42 hours against a few hours for the opioids people usually switch from — the general course of that sharper withdrawal is on the opioid withdrawal timeline page. The drug is still occupying receptors on day two. That single number explains the two surprises everyone reports: withdrawal does not start the next morning, and once it arrives it does not leave quickly.

The label, in its own words

The prescribing information says the withdrawal syndrome is typically milder than with full agonists and may be delayed in onset, and says to taper rather than stop. Milder is real and welcome; delayed is the part that catches people planning a long weekend. The drug is slow to leave, so the bill arrives slow and pays out slowly.

What "peak" actually means here

For short-acting opioids the peak is a day you can circle. For buprenorphine it is a band: symptoms build across the first several days, and when they ease depends on the taper, the dose and the person. Anyone selling you an exact worst day is selling folklore. The measured trials below show ranges, not dates.

The symptoms, in the order people meet them

The list is stable across the clinical literature: anxiety and restlessness first, then the body symptoms (muscle aches, sweating, chills, yawning, tearing, a runny nose), then the stomach symptoms (cramps, nausea, diarrhea), and underneath all of it the broken sleep. The physical storm settles over the first weeks; what lingers is sleep that will not hold and a mood that sits low, and those two are the tail people mean when they say it lasts.

Insomnia and restless legs

The two most complained-about symptoms and the last to leave. Sleep fragments early and stays light for weeks; restless legs arrive with the first nights and pace the floor with you. Both respond to the boring measures (schedule, morning light, no caffeine after noon) plus, in a guided taper, to symptomatic medication a prescriber can add.

What is not on the list

No seizures, no delirium: opioid withdrawal, unlike alcohol or benzodiazepine withdrawal, is not the dangerous kind in an otherwise healthy adult. That is worth saying plainly because people delay stopping out of fear of the wrong risk. The dangerous part of this timeline is not the withdrawal; it is the relapse after it, with tolerance gone.

What the studies actually measured

Everyone publishes a day-by-day timeline; almost nobody says where the days come from. The honest version comes from the randomized taper trials, which measured something narrower and more useful: what happens at different taper speeds. We read the Cochrane review of the seven trials and the primary papers, and the picture is more interesting than any day-by-day chart.

  • Ling 2009 (CTN)

    Tapers compared
    7 days vs 28
    Population
    heroin users, outpatient
    What was measured
    end of taper: 44% vs 30% abstinent; at 1 and 3 months no difference (17% vs 13%)

  • Sigmon 2013 (JAMA)

    Tapers compared
    1 vs 2 vs 4 weeks, then naltrexone
    Population
    prescription opioid users
    What was measured
    4-week: mild, stable course; 1-2 weeks: sharp rise the week after the last dose; better outcomes at 4 weeks

  • Wang 1996

    Tapers compared
    14 days vs 8 weeks
    Population
    opioid users
    What was measured
    rapid: muscle aches in all, lengthy insomnia; gradual: minimal complaints

  • Amass 1994

    Tapers compared
    12 vs 36 days
    Population
    opioid users, outpatient
    What was measured
    observers saw no severity difference; patients felt the fast one build faster

  • Marsch 2016

    Tapers compared
    28 vs 56 days
    Population
    adolescents
    What was measured
    longer taper, longer in treatment; clinic visit frequency changed completion

  • Assadi 2004

    Tapers compared
    2 vs 5 days
    Population
    inpatient
    What was measured
    no severity difference; the rapid group peaked earlier

  • Hopper 2005

    Tapers compared
    1 vs 3 days
    Population
    inpatient
    What was measured
    no difference in withdrawal scores or adjunct medication
The randomized taper trials, by regimen and result (read 15 October 2026 from the Cochrane review and the primary papers)

Fast feels worse, measurably

The consistent finding across the outpatient trials: the week after the last dose of a short taper is the hard week. Sigmon’s one- and two-week groups showed a sharp rise in withdrawal right there; Wang’s rapid group reported muscle aches across the board and long insomnia; Amass’s patients rated their withdrawal as building faster even when observers saw no difference. If your taper is short, that week is the thing to plan.

Longer was not proven better

And here the folklore breaks. Ling’s CTN trial, the largest of them, found the 7-day taper was not worse than 28 days, with 44% versus 30% abstinent at the end and no difference a month or three later. Sigmon found the four-week taper kinder and more successful in prescription-opioid users who then went on naltrexone. The honest summary: taper length matters less than who you are and what comes after the last dose.

What this means for your timeline

No published day-count is your day-count. The trials say the shape (late start, build, tail) is real and the speed of your taper moves the hard week, but the duration of symptoms in weeks is written by your dose history, not by a chart. This is why the plan belongs to a prescriber and the timeline below is a shape, not a schedule.

Is it dangerous

Two different answers, and both matter. The withdrawal itself: miserable, not fatal, in a healthy adult. Opioid withdrawal does not carry the seizure risk that alcohol and benzodiazepine withdrawal do. The danger is downstream: tolerance falls during abstinence, and a return to the old dose is now an overdose. NIDA’s guidance treats that post-withdrawal window as the lethal one, and it is why naloxone and a follow-up plan belong in every taper.

Precipitated withdrawal: the one that is avoidable

There is one version of this misery that is entirely preventable. Starting buprenorphine while a full agonist still occupies the receptors kicks it off at once, and the result is sudden, full-force withdrawal within minutes to hours. The prevention is the waiting rule: begin only when real withdrawal has started. Every induction guide exists to enforce that wait, and it is the single best reason the first dose belongs with a clinician, not a couch.

Cold turkey versus a taper

Stopping without a taper is legal, survivable, and the hard way: the whole course arrives at full strength, alone, at whatever your last dose was. The label itself advises tapering. A guided taper does not erase the experience; it changes the shape, spreading it and shrinking the peak, with symptomatic help available for the sleep and stomach weeks. People who stopped both ways describe the difference as weather versus a wall.

Getting through the weeks

The measures that work are boring and specific: a fixed wake time, morning daylight, no caffeine after noon, walking daily, fluids and actual meals for the stomach weeks, and a person you report to. The trials add the two that need a prescriber: symptomatic medication for the rough week, and a decision about naltrexone or follow-up before the last dose, not after. Recovery environments matter here too; the structured-housing side of that question is on our sober living rules page.

What we read, and how

On 15 October 2026 we read the primary evidence rather than the timelines built from it: the Cochrane review of buprenorphine taper rates (seven randomized trials, with regimens and results), Sigmon 2013 in JAMA Psychiatry (the 1-, 2- and 4-week comparison with its naltrexone phase), and the Ling 2009 Clinical Trials Network numbers (7 versus 28 days in heroin users). The label facts come from the FDA prescribing information via DailyMed. The table and the conclusions drawn from it are ours.

The limits of this reading

The trials are small, old and built for different populations; Cochrane itself says no meta-analysis was possible. None of them measures the thing a search engine wants, which is your personal day count. What they do measure is real: taper speed moves the hard week, and population and aftercare decide the rest. For the dose-by-dose schedule, the answer is a prescriber, not a page, including ours.

What the trials say about taper length: fast tapers show a sharp rise in the week after the last dose, slow tapers run milder but did not win on outcomes in the largest trial
Speed moves the hard week. Population and aftercare move the ending.
Two cards comparing cold turkey and a guided taper: the whole course at full force alone versus graded reductions under a prescriber
A taper does not erase the experience; it changes the shape and shrinks the peak.
Precipitated withdrawal explained: starting buprenorphine while a full agonist still occupies receptors kicks it off at once; waiting for real withdrawal before the first dose prevents it
The one version of this misery that is entirely avoidable, avoided by a timer.
Is Suboxone withdrawal dangerous: the withdrawal itself is miserable but not fatal in a healthy adult; the relapse after it, with tolerance gone, is what kills
No seizures on this drug. The danger is downstream, and it has a plan: naloxone plus follow-up.

Where this sits in the system of care

Addiction treatment is organised into levels of care, and clinicians choose between them using the ASAM criteria (six dimensions covering withdrawal risk, medical and psychiatric conditions, readiness, relapse risk and, decisively, the environment you return to. Facilities are licensed by the state and many hold additional accreditation from bodies such as the Joint Commission or CARF; that status is worth confirming for any specific programme. Percentages below are our count of how many facilities in the federal directory report offering each level of care.

  1. Detox19.5% of facilitiesmedical withdrawal management, 3–7 daysDetox vs rehab
  2. Residential21.4% of facilitieslive on site, 24-hour staffingInpatient vs outpatient
  3. PHP20–30 structured hours a week, sleep at homePHP vs IOP
  4. IOP9–19 hours a week, usually compatible with workPHP vs IOP
  5. Standard outpatient85.4% of facilities1–8 hours a week, the maintenance levelMutual aid options
“Remaining in treatment for an adequate period of time is critical.”

Programmes for specific groups

Facilities also report dedicated programming, and the coverage is wider than most people expect, worth asking about before assuming a programme will not fit. From our count: 42.7% run programmes for adolescents, 39.2% for veterans, 38% for pregnant and postpartum women, and 25% provide services in Spanish. Medication for opioid use disorder is available at 59.2% (buprenorphine) and 13.7% (methadone).

Cost and coverage vary by level: residential care is the tier insurers scrutinise most and almost always requires prior authorisation before admission. See what your plan covers and how to pay without insurance. Family involvement is a standard part of most programmes, and aftercare planning ( step-down to a lower level, sober living, relapse prevention) should be discussed before admission, not at discharge. If a mental health condition is also present, ask specifically whether the programme is staffed for co-occurring disorders: 69.5% of facilities in the directory report treating them, but that is a self-reported field worth confirming.

Two cards on where tapering happens: outpatient with a prescriber and a schedule, and the federal locator for finding one with taper experience
No hospital bed needed for most; the plan and the follow-up are the medical parts.
What this timeline is not for: not alcohol or benzodiazepines, whose withdrawals can kill, and not kratom, which has no approved therapy
Different mechanisms, different pages. This one is opioid-only and specifically buprenorphine.
When the answer is a prescriber and not a page: pregnancy, heart conditions and other medications change the plan, and a taper written for your dose beats any published schedule
The trials agree on this much: the plan has to fit the person.
Two questions for the prescriber: how fast a taper for my dose and history, and what comes after the last dose, naltrexone or not, sleep plan, follow-up week
The tail has a plan too. The best-ending trials built the next step in before the last dose.
Bar chart of medication for opioid use disorder availability: buprenorphine at 59.2% of facilities, methadone at 13.7%, certified opioid treatment programmes at 12.8%
The four-to-one gap between buprenorphine and methadone availability is a regulatory fact, not a clinical judgement about which works better.
Bar chart of how many US treatment facilities offer each level of care: outpatient 85.4%, residential 21.4%, medical detox 19.5%, hospital inpatient 5.9%
Outpatient care is nearly universal; residential and detox are the scarce tiers. That scarcity is part of why they cost what they do and why waits exist.
Diagram of the step-down pathway through addiction treatment: detox, residential, partial hospitalisation, intensive outpatient, then outpatient and aftercare
Nobody needs every step. The ladder exists so that support can be reduced as stability improves, not so that everyone starts at the top.
Checklist of the six ASAM assessment dimensions: withdrawal risk, medical conditions, emotional and behavioural conditions, readiness to change, relapse potential, and recovery environment
This is the framework US programmes and insurers actually use. The sixth dimension — what home is like — is the one families most often underestimate.
Checklist of six questions to ask a treatment facility about network status, prior authorisation, all-in cost, medication availability, aftercare and accreditation
How plainly a programme answers these is itself information about how it operates.
Bar chart of payment types accepted by US addiction treatment facilities: cash 91.6%, private insurance 80.7%, Medicaid 83.4%, Medicare 55.2%, state-financed 54.5%, military 49.6%, sliding scale 40.0%, payment assistance 22.5%
Accepting your insurer is not the same as your plan covering the level of care you need. The two questions have to be asked separately.
Three figures: 69.5% of facilities treat co-occurring disorders, 59.8% offer trauma-informed care, 19.5% run medical detox
Co-occurring capability is self-reported. Ask what it means concretely, which clinicians are on staff, and whether psychiatric medication can be prescribed and reviewed on site.
Table showing when to call 911, 988 or the SAMHSA National Helpline for overdose, immediate danger, suicidal thoughts, severe distress and treatment questions
All three are free and staffed around the clock. 988 is the Suicide & Crisis Lifeline; the SAMHSA National Helpline is 1-800-662-4357.

Common questions

How long does Suboxone withdrawal last?

The physical symptoms build over the first several days and settle over the first weeks; what lingers is sleep and mood, for weeks more. An exact day-count does not exist because the drug leaves slowly and the trials measured shapes, not dates. The honest answer: the worst is front-loaded into the first week or two after the last dose, the tail is insomnia and low mood, and the tail is what a prescriber’s plan is for.

When does Suboxone withdrawal start?

Later than with short-acting opioids. Buprenorphine’s half-life is 24 to 42 hours, so the day after the last dose is usually quiet; symptoms build across the following days. People expecting a next-morning wall get confused by the calm, and people planning around a weekend get caught by the delay.

Is Suboxone withdrawal dangerous?

The withdrawal itself is miserable but not fatal in a healthy adult: opioid withdrawal does not cause seizures the way alcohol or benzodiazepine withdrawal can. The lethal risk is after it: tolerance falls fast, and returning to the old dose can be an overdose. Naloxone and a follow-up plan belong in every taper.

What are the symptoms of Suboxone withdrawal?

In the order people usually meet them: anxiety and restlessness, then muscle aches, sweating, chills, yawning and a runny nose, then stomach cramps, nausea and diarrhea, with broken sleep underneath all of it and restless legs at night. The physical list settles in weeks; sleep and mood are the tail.

How long should a Suboxone taper last?

The trials answer honestly: it depends on the person more than the calendar. The largest trial found no advantage to 28 days over 7 in heroin users; a trial in prescription-opioid users found four weeks kinder and more successful with naltrexone after. Short tapers concentrate the hard week; long ones spread it. The schedule belongs to your prescriber.

What is precipitated withdrawal?

The preventable one: taking buprenorphine while a full agonist still occupies the receptors kicks it off at once, producing sudden, severe withdrawal within minutes to hours. The prevention is waiting for real withdrawal before the first dose. This is the strongest reason induction belongs with a clinician.

Can you quit Suboxone cold turkey?

It is legal and survivable, and it is the hard way: the full course arrives at once, at whatever your dose was. The FDA label advises tapering, and a guided taper changes the shape, spreading symptoms and shrinking the peak, with medication available for the rough weeks.

What helps with Suboxone withdrawal?

The boring list works: fixed wake time, morning daylight, no afternoon caffeine, daily walking, fluids and real food. From a prescriber: symptomatic medication for the stomach and sleep weeks, and a decision about naltrexone or follow-up made before the last dose. Structure helps too: the housing side of that is on our [sober living rules](/guides/sober-living-rules) page, and the weeks after are where the measured map lives: [relapse warning signs](/guides/relapse-warning-signs).

Sources

Compare levels of care

Check what your plan covers

How this page was made

Who wrote it:
the Westbrook Recovery editorial team : researchers and writers, not clinicians. No doctor has reviewed this page, and we do not claim otherwise. What that means in practice: we report what public clinical sources say and show you where to read them, rather than offering a clinical opinion of our own.
Checked against:
6 primary sources listed above: federal agency material and published clinical criteria. Where a figure varies by state, plan or facility, we say so instead of publishing a number that looks authoritative and is not.
Original analysis:
the facility proportions on this page are our own count of SAMHSA’s public directory. The full method is documented , including what we count, what we deliberately do not publish, and an error the approach caught. You can repeat the pull and check the numbers.
Last reviewed:
. This date changes when the content is actually re-checked, not automatically on every visit.
What this page is not:
a medical recommendation, a diagnosis, or a referral. Decisions about levels of care and medication belong with a clinician who knows your history. We do not operate facilities, take placement fees, or receive payment for sending anyone anywhere.

Related on this site

More guides

Weighing levels of care? See PHP vs IOP and what your insurance covers.

This page is information, not medical or legal advice. Laws on commitment and treatment differ by state. If you are in crisis, call or text 988 in the US, or reach the SAMHSA National Helpline at 1-800-662-4357 — free, confidential, 24/7.